| 孙雪林,彭旭东,黄厚源,等.度伐利尤单抗与曲美木单抗联合治疗转移性非小细胞肺癌有效性和安全性的Meta分析[J].中国临床保健杂志,2024,27(6):822-826. |
| 度伐利尤单抗与曲美木单抗联合治疗转移性非小细胞肺癌有效性和安全性的Meta分析 |
| Meta-analysis of the efficacy and safety of the combination of Drivarilumab and Tremelimumab in the treatment of metastatic non-small cell lung cancer |
| 投稿时间：2024-06-05 |
| DOI：10.3969/J.issn.1672-6790.2024.06.022 |
| 中文关键词: 癌,非小细胞肺 抗体,单克隆 治疗结果 药物相关性副作用和不良反应 Meta分析 |
| 英文关键词: Carcinoma,non-small-cell lung Antibodies,monoclonal Treatment outcome Drug-related side effects and adverse reactions Meta-analysis 〖FL |
| 基金项目:国家自然科学基金面上项目(82373272)；中央高水平医院临床科研业务费资助项目(BJ-2023-200) |
|
| 摘要点击次数: 846 |
| 全文下载次数: 877 |
| 中文摘要: |
| 目的 系统评价度伐利尤单抗(durvalumab)联合曲美木单抗(tremelimumab)治疗转移性非小细胞肺癌(mNSCLC)的有效性和安全性。方法 计算机检索万方、中国知网、维普、The Cochrane Library、PubMed、Embase、Web of Science数据库,检索度伐利尤单抗与曲美木单抗联合治疗非小细胞肺癌的研究,检索范围自2000年1月1日 至 2023 年 11 月28日。由不同的研究者独立进行文献筛选、数据提取、文献偏倚风险评估,对提取后的数据进行Meta分析。结果 与对照组相比,度伐利尤单抗与曲美木单抗联合治疗组的总生存率(OS)、无进展生存期(PFS),差异无统计学意义(P＞0.05)；2组不良反应发生率比较,差异有统计学意义(P＜0.05)。结论 相比于三联/传统疗法,度伐利尤单抗联合曲美木单抗治疗mNSCLC的不良反应较少。 |
| 英文摘要: |
| Objective To systematically evaluate the efficacy and safety of durvalumab in combination with tremelimumab in the treatment of metastatic non-small cell lung cancer.Methods Wanfang,CNKI,and VIP,The Cochrane Library,PubMed,Embase,Web of Science databases were searched for studies of durvalumab in combination with tremelimumab in the treatment of non-small-cell lung cancer from 1st January 2000 to 28th November 2023.Literature screening,data extraction,risk of bias assessment were performed independently by different researchers,and Meta-analysis was performed on the extracted data.Results There was no significant difference in overall survival (OS),progression-free survival (PFS),and a significant reduction in the incidence of adverse events in the combination treatment group of duvarizumab and trimethoprim compared with the control group.Conclusion Compared to triple/traditional therapy,the combination of Drivarilumab and Tremelimumab has fewer adverse reactions in the treatment of metastatic non-small cell lung cancer. |
|
查看全文
|
| 关闭 |
|
|
|